| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Rob Bresnahan PA08 | 1 | 1 | +$0 | Bought May 29, 25 |
| Byron Donalds FL19 | 2 | −$16.0K | Sold Mar 20, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| May 29, 25 | Rob Bresnahan PA08 | Self | Buy | $1,001 - $15,000 | Jun 23, 25 (25d) | |
| May 16, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | Jun 9, 25 (24d) | |
| Mar 20, 25 | Byron Donalds FL19 | Spouse | Sell | $1,001 - $15,000 | Apr 14, 25 (25d) | |
| Mar 20, 25 | Byron Donalds FL19 | Self | Sell | $1,001 - $15,000 | Apr 14, 25 (25d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Rizzo Daniel JOfficer | Sale at price 276.21 - 276.53 per share. | 4.8K | $1.34M |
| Oct 1, 2026 | Faddis Jonathan WGeneral Counsel | Stock Gift at price 0.00 per share. | 803 | — |
| Sep 30, 2026 | Zuppas Eleni Nitsa APresident | — | 2.2K | — |
| Sep 30, 2026 | Van Wagener BrianChief Financial Officer | — | 1.6K | — |
| Sep 30, 2026 | Kondath VipinOfficer | — | 168 | — |
| Sep 30, 2026 | Rizzo Daniel JOfficer | — | 1.7K | — |
| Sep 30, 2026 | Schwenger Thomas DPresident | — | 2.9K | — |
| Sep 30, 2026 | Faddis Jonathan WGeneral Counsel | — | 1.6K | — |
| Sep 13, 2026 | Schwenger Thomas DPresident | Sale at price 265.20 per share. | 1K | $265.20K |
| Sep 8, 2026 | Hung Priscilla CDirector | Sale at price 261.04 per share. | 750 | $195.78K |
| Aug 31, 2026 | Cabral Timothy SDirector | — | 477 | — |
| Aug 31, 2026 | Ritter GordonDirector | — | 541 | — |
| Aug 31, 2026 | Sekhri Paul JaiDirector | — | 460 | — |
| Aug 31, 2026 | Carges Mark TDirector | — | 493 | — |
| Aug 31, 2026 | Mohr Marshall LDirector | — | 525 | — |
| Aug 31, 2026 | Hedley Mary LynneDirector | — | 477 | — |
| Aug 31, 2026 | Wallach Matthew JDirector | — | 460 | — |
| Aug 31, 2026 | Hung Priscilla CDirector | — | 477 | — |
| Aug 26, 2026 | Schwenger Thomas DPresident | Sale at price 281.33 per share. | 10K | $2.81M |
| Aug 26, 2026 | Schwenger Thomas DPresident | Conversion of Exercise of derivative security at price 154.00 per share. | 10K | $1.54M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.7 | -10.7 | -3.5 | -11.2 | 11.8 | 1.8 | 14.8 | 40.2 | -0.1 | 3.6 | +32.5% | ||
| 2025 | 10.9 | -3.9 | 3.3 | 0.9 | 19.7 | 3.0 | -1.3 | -5.3 | 10.7 | -2.3 | -17.5 | -7.1 | +6.2% |
| 2024 | 7.7 | 8.7 | 2.7 | -14.3 | -12.2 | 5.0 | 4.9 | 12.8 | -3.0 | -0.5 | 9.1 | -7.7 | +9.2% |
| 2023 | 5.7 | -2.9 | 10.9 | -2.6 | -7.5 | 19.3 | 3.3 | 2.2 | -2.5 | -5.3 | -9.5 | 10.4 | +19.3% |
| 2022 | -7.4 | -3.2 | -7.2 | -14.4 | -6.4 | 16.3 | 12.9 | -10.9 | -17.3 | 1.9 | 13.4 | -15.2 | −36.8% |
| 2021 | 1.5 | 1.3 | -6.7 | 8.1 | 3.1 | 6.7 | 7.0 | -0.2 | -13.2 | 10.0 | -10.9 | -9.6 | −6.2% |
| 2020 | 4.2 | -3.2 | 10.1 | 22.0 | 14.7 | 7.1 | 12.9 | 6.7 | -0.4 | -4.0 | 2.5 | -1.7 | +93.6% |
| 2019 | 22.1 | 8.1 | 7.6 | 10.3 | 10.3 | 5.1 | 2.3 | -3.3 | -4.8 | -7.1 | 5.2 | -5.7 | +57.5% |
| 2018 | 13.7 | 10.9 | 4.8 | -4.0 | 10.3 | -0.6 | -1.6 | 38.0 | 4.3 | -16.1 | 5.3 | -7.1 | +61.6% |
| 2017 | 4.0 | 3.2 | 17.4 | 4.6 | 18.5 | -3.5 | 4.0 | -6.7 | -5.2 | 8.0 | -1.2 | -8.2 | +35.8% |
| 2016 | -16.5 | 0.8 | 3.1 | 9.9 | 19.8 | 3.6 | 11.3 | 7.7 | 0.9 | -5.9 | 19.6 | -12.4 | +41.1% |
| 2015 | 8.9 | 7.3 | -17.3 | 4.0 | 2.1 | 3.4 | -4.0 | -3.8 | -9.6 | 8.4 | 13.8 | -0.0 | +9.2% |
| 2014 | -1.0 | 11.0 | -24.4 | -28.1 | 9.1 | 21.4 | -6.5 | 25.9 | -6.0 | 5.7 | 10.3 | -19.6 | −17.7% |
| 2013 | 4.1 | -20.7 | −17.5% |
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
Buy / hold / sell counts